Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Leukemia. 2019 Aug 19;34(1):210–223. doi: 10.1038/s41375-019-0540-7

Figure 4. Increased anti-MM activities of BCMA-specific CTL generated with BCMA72-80 peptide encapsulated nanoparticles against primary CD138+ tumor cells from myeloma patients.

Figure 4.

Figure 4.

Figure 4.

A: Background functional activities by BCMA-CTL alone (no tumor cells encounted). B and C: Anti-MM activities of PLGA/peptide-CTL against primary CD138+ tumor cells from (B) HLA-A2+ MM Patient #1 or from (C) HLA-A2+ MM Patient #2. D: Summary of three independent experiments (N=3) showing the HLA-A2 restricted anti-tumor activities of BCMA-CTL against primary CD138+ tumor cells from myeloma patients.